Heron Therapeutics (HRTX) Competitors $1.65 -0.03 (-1.79%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends HRTX vs. COLL, SEPN, BCAX, ZYME, GYRE, PSTX, COGT, PAHC, NUVB, and AVBPShould you be buying Heron Therapeutics stock or one of its competitors? The main competitors of Heron Therapeutics include Collegium Pharmaceutical (COLL), Septerna (SEPN), Bicara Therapeutics (BCAX), Zymeworks (ZYME), Gyre Therapeutics (GYRE), Poseida Therapeutics (PSTX), Cogent Biosciences (COGT), Phibro Animal Health (PAHC), Nuvation Bio (NUVB), and ArriVent BioPharma (AVBP). These companies are all part of the "pharmaceutical products" industry. Heron Therapeutics vs. Collegium Pharmaceutical Septerna Bicara Therapeutics Zymeworks Gyre Therapeutics Poseida Therapeutics Cogent Biosciences Phibro Animal Health Nuvation Bio ArriVent BioPharma Collegium Pharmaceutical (NASDAQ:COLL) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations, community ranking and profitability. Do analysts recommend COLL or HRTX? Collegium Pharmaceutical currently has a consensus target price of $42.60, suggesting a potential upside of 37.86%. Heron Therapeutics has a consensus target price of $5.67, suggesting a potential upside of 243.43%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Heron Therapeutics is more favorable than Collegium Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Collegium Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60Heron Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation & earnings, COLL or HRTX? Collegium Pharmaceutical has higher revenue and earnings than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCollegium Pharmaceutical$599.25M1.66$48.15M$2.3213.32Heron Therapeutics$137.74M1.82-$110.56M-$0.18-9.17 Does the MarketBeat Community prefer COLL or HRTX? Heron Therapeutics received 279 more outperform votes than Collegium Pharmaceutical when rated by MarketBeat users. Likewise, 69.09% of users gave Heron Therapeutics an outperform vote while only 65.25% of users gave Collegium Pharmaceutical an outperform vote. CompanyUnderperformOutperformCollegium PharmaceuticalOutperform Votes38565.25% Underperform Votes20534.75% Heron TherapeuticsOutperform Votes66469.09% Underperform Votes29730.91% Which has more volatility and risk, COLL or HRTX? Collegium Pharmaceutical has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.67, suggesting that its stock price is 67% more volatile than the S&P 500. Do institutionals & insiders hold more shares of COLL or HRTX? 80.0% of Heron Therapeutics shares are held by institutional investors. 4.0% of Collegium Pharmaceutical shares are held by company insiders. Comparatively, 5.8% of Heron Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media refer more to COLL or HRTX? In the previous week, Collegium Pharmaceutical had 4 more articles in the media than Heron Therapeutics. MarketBeat recorded 4 mentions for Collegium Pharmaceutical and 0 mentions for Heron Therapeutics. Collegium Pharmaceutical's average media sentiment score of 1.63 beat Heron Therapeutics' score of 0.94 indicating that Collegium Pharmaceutical is being referred to more favorably in the media. Company Overall Sentiment Collegium Pharmaceutical Very Positive Heron Therapeutics Positive Is COLL or HRTX more profitable? Collegium Pharmaceutical has a net margin of 14.78% compared to Heron Therapeutics' net margin of -20.31%. Collegium Pharmaceutical's return on equity of 104.67% beat Heron Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Collegium Pharmaceutical14.78% 104.67% 18.38% Heron Therapeutics -20.31%N/A -12.72% SummaryCollegium Pharmaceutical beats Heron Therapeutics on 9 of the 17 factors compared between the two stocks. Ad Porter & CompanyA conspiracy Trump won’t unsealNew documentary reveals the lost wealth-building secret hidden deep within ancient religious texts from almost every civilization… an investment one expert says is “so perfect that only God could have created it.” Watch it now to discover how this asset that you’ve likely never considered before can produce returns so safe, secure, and endless it is nothing short of miraculous.This is the untold, true story of God’s Investment. Get Heron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HRTX vs. The Competition Export to ExcelMetricHeron TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$250.96M$6.85B$5.14B$9.31BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-9.1710.75135.1817.53Price / Sales1.82287.861,235.42140.39Price / CashN/A56.6540.6537.95Price / Book-7.175.394.884.92Net Income-$110.56M$152.04M$118.97M$225.78M7 Day Performance-2.37%-4.32%16.19%-1.58%1 Month Performance41.03%2.80%16.02%6.67%1 Year Performance-5.17%17.30%34.95%22.48% Heron Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HRTXHeron Therapeutics4.2144 of 5 stars$1.65-1.8%$5.67+243.4%-8.8%$250.96M$137.74M-9.17300COLLCollegium Pharmaceutical3.9712 of 5 stars$30.57+1.6%$42.60+39.4%+4.3%$985.88M$599.25M12.97210News CoveragePositive NewsSEPNSepterna1.7246 of 5 stars$22.05-1.5%$43.67+98.0%N/A$979.02MN/A0.00N/ABCAXBicara TherapeuticsN/A$17.57+0.4%$43.00+144.7%N/A$956.09MN/A0.0032ZYMEZymeworks3.0526 of 5 stars$13.75+9.3%$18.83+37.0%+46.9%$947.10M$76.01M-9.25290Analyst UpgradePositive NewsGYREGyre Therapeutics0.3745 of 5 stars$10.12+5.0%N/A-54.6%$946.43M$105.03M0.0040News CoverageGap UpPSTXPoseida Therapeutics3.7029 of 5 stars$9.52+0.1%$9.50-0.2%+193.2%$930.77M$64.70M-15.10260COGTCogent Biosciences2.265 of 5 stars$8.35+2.5%$14.83+77.6%+67.8%$922.34MN/A-3.2980Short Interest ↑PAHCPhibro Animal Health4.1953 of 5 stars$22.71+0.2%$19.00-16.3%+97.9%$919.82M$1.05B52.561,940Analyst ForecastNews CoverageNUVBNuvation Bio1.9641 of 5 stars$2.71+3.8%$6.60+143.5%+99.6%$912.11MN/A0.0060AVBPArriVent BioPharma1.1598 of 5 stars$26.78+0.2%$36.80+37.4%N/A$902.41MN/A0.0040Short Interest ↑Positive News Related Companies and Tools Related Companies Collegium Pharmaceutical Competitors Septerna Competitors Bicara Therapeutics Competitors Zymeworks Competitors Gyre Therapeutics Competitors Poseida Therapeutics Competitors Cogent Biosciences Competitors Phibro Animal Health Competitors Nuvation Bio Competitors ArriVent BioPharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HRTX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
